Amalgamated Bank Janux Therapeutics, Inc. Call Options Transaction History
Amalgamated Bank
- $13.6 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding JANX
# of Institutions
187Shares Held
55MCall Options Held
850KPut Options Held
217K-
Ra Capital Management, L.P. Boston, MA11.2MShares$307 Million4.7% of portfolio
-
Janus Henderson Group PLC London, X04.7MShares$129 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$80.2 Million3.15% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.78MShares$76.2 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$66.4 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.14B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...